ArticleClinical rheumatology2026
Diagnostic delay in psoriatic disease: cutaneous and musculoskeletal pathways in a Mexican tertiary-care cohort.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriatic disease (PsD) is frequently diagnosed late. Understanding its cutaneous and musculoskeletal diagnostic pathways is crucial for improving early recognition.
objectivesTo describe and compare the cutaneous and musculoskeletal diagnostic pathways in patients with PsD, identify factors associated with diagnostic delay, and analyze trends in time to diagnosis by pathway.
methodsCross-sectional study using a structured questionnaire. Time to diagnosis was defined separately for the cutaneous and musculoskeletal pathways, from symptom onset to the first physician-confirmed diagnosis of psoriasis (Pso) or psoriatic arthritis (PsA). Diagnostic delay was defined as time to diagnosis > 12 months. Logistic and linear regression models assessed associated factors and temporal trends.
resultsWe included 143 patients with PsD: 54 had Pso without PsA at cohort entry, and 89 had rheumatologist-confirmed PsA. Median time to diagnosis was 12.2 months in both pathways; diagnostic delay occurred in 58% of the cutaneous and 61.8% of the musculoskeletal pathways. In the cutaneous pathway, longer time to seek care increased the odds of delay, whereas a correct diagnosis at the first visit was protective. In the musculoskeletal pathway, older age and longer time to seek care increased the odds of delay, while specialist evaluation and DMARD initiation at first visit were protective. A more recent calendar year of symptom onset was associated with shorter time to diagnosis in both pathways.
conclusionsDiagnostic delays in PsD persist despite recent improvements. Distinct determinants across the cutaneous and musculoskeletal pathways highlight the need for earlier Pso recognition and more efficient referral for musculoskeletal symptoms suggestive of PsA. Keypoints • In this tertiary PsD cohort, the median time to diagnosis was 12 months in both the cutaneous and musculoskeletal diagnostic pathways, and more than half of the patients experienced delays >12 months. • In the cutaneous pathway, the main driver of delay was the time patients waited before seeking medical attention for skin lesions, whereas correct diagnosis at the first visit was protective. • In the musculoskeletal pathway, older age and delayed consultation for musculoskeletal symptoms were associated with longer delays, whereas early specialist assessment and DMARD initiation characterized more efficient pathways. • Time to diagnosis decreased significantly across calendar years in both pathways, although the persistently high delay burden underscores the need for stronger coordination among primary care, dermatology, and rheumatology.
Indexed as
Identifiers
42538474What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.